01—Abstract
Summary
Summary of the 8-K filed April 9, 2026. Cited figures are marked; the original filing is the authoritative source.
Becton, Dickinson and Company (BDX) disclosed in an 8-K filed April 9, 2026 that Richard (Rick) E.
Byrd, Executive Vice President and President of the Interventional segment, has informed the company of his intention to retire. Byrd notified BD on April 6, 2026, and will remain in his role through June 2026. The filing reports no financial results, guidance changes, or compensation arrangements tied to the departure, and the disclosure is routine in nature.
For investors, the key near-term item is leadership continuity in the Interventional segment, which Byrd has led since September 2022 and which covers products such as vascular access and related interventional technologies. BD has stated its intention to name a successor before Byrd's retirement date, so investors should watch for that announcement, which would likely indicate whether the company is filling the role internally or externally and whether strategic priorities for the segment will shift.
Overall, this filing is a low-materiality governance update rather than a fundamental change to BD's financial outlook. Byrd's tenure, which includes leadership of Medication Delivery Solutions and Preanalytical Systems and the COVID-19 manufacturing scale-up, gives context to the transition, but the filing itself does not quantify any impact on revenue, margins, or segment performance.
02—Key points
Key Highlights
- Richard E. Byrd, EVP and President of the Interventional segment, informed BD on April 6, 2026 of his intention to retire.
- Byrd will remain in his role through June 2026, providing a defined transition window.
- BD intends to name a successor before Byrd's retirement date; the identity and timing of the successor were not disclosed in the filing.
- Byrd has led the Interventional segment since September 2022 and spent nearly 25 years with BD, including roles as worldwide president of Medication Delivery Solutions and Preanalytical Systems.
- CEO Tom Polen credited Byrd with expanding BD's leadership in Vascular Access Management, advancing the 'One-Stick Hospital Stay' vision, and leading manufacturing scale-up during COVID-19.
- The filing contains no financial results, guidance changes, or disclosed severance or compensation arrangements related to the departure.
- The press release was furnished under Item 7.01 (Regulation FD) and is not deemed 'filed' under the Exchange Act.
03—Questions
Frequently Asked Questions
Why is this filing important to investors?
It discloses a senior leadership change at the segment level. Although the Interventional segment is a meaningful part of BD's portfolio, the 8-K contains no financial impact, and the change was announced with a planned transition period, which generally reduces disruption risk.
Who is leaving and what role did they hold?
Richard (Rick) Byrd, Executive Vice President and President of the Interventional segment. He has held that position since September 2022 and has been with BD for nearly 25 years.
When will the departure take effect?
Byrd will remain in his role through June 2026. The filing does not give an exact retirement date, but states that BD intends to name a successor before that date.
Does this change BD's financial outlook?
The filing does not report any change to financial results or guidance, and it does not quantify any financial effect of the retirement. Investors should monitor the successor announcement and any commentary on segment strategy in upcoming earnings calls.
What should investors watch for next?
The key follow-up is BD's announcement of Byrd's successor, including whether the appointment is internal or external and whether it signals any change in strategy or priorities for the Interventional segment.
04—Continue